1292784-48-5

Basic information

• Product Name: N-Benzyl-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyl amide
• Synonyms: N-Benzyl-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyl amide
• CAS NO: 1292784-48-5
• Molecular Weight: 345.398
• Mol File: 1292784-48-5.mol

Chemical Properties

• CAS DataBase Reference: N-Benzyl-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyl amide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzyl-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyl amide(1292784-48-5)
• EPA Substance Registry System: N-Benzyl-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyl amide(1292784-48-5)

Safety Data

• Hazardous Substances Data: 1292784-48-5(Hazardous Substances Data)

Upstream product

• 17417-00-4 methyl 2-hydroxy-3-methylbutanoate 
• 13223-25-1 2-chloro-4,6-dimethoxypyrimidine 
• 127012-42-4 (S)-methyl 2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methylbutanoate 
• 127010-71-3 2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methyl-butyric acid 
• 100-46-9 benzylamine 

Relevant articles and documents

NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF

The present invention relates to novel 2,4-pyrimidine derivatives and a use thereof, and more particularly, to pyrimidine derivatives which are effective for systemic lupus erythematosus, a composition for preventing and treating systemic lupus erythematosus comprising the same as an active ingredient and a method for screening the same. The present inventors found novel materials inhibiting surface translocation of gp96 by mimicking a function of AIMP1 which is a molecular anchor for an intracellular residence of gp96, and identified in vitro and in vivo activity of the materials for preventing and treating SLE by alleviating SLE plasma in autoimmune diseases. Therefore, the present invention provides a novel method for screening a therapeutic agent for SLE, and preventing or treating SLE using the mechanism.